Advertisement

Picture [iito] Made Without Love 650x80px
Organisation › Details

Moderna Therapeutics Inc.

Moderna is pioneering messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of disease conditions. The company currently plans to develop and commercialize its innovative mRNA drugs through a combination of strategic relationships as well as newly formed ventures, including Onkaido LLC, focused on oncology drug development. Founded by Flagship VentureLabs™, Cambridge-based Moderna is privately held and currently has strategic agreements with AstraZeneca and Alexion Pharmaceuticals. *

 

Period Start 2013-03-24 existent
Period End 2018-08-01 renamed
  Group Moderna (Group)
  Today Moderna Inc. (Nasdaq: MRNA)
  Successor Moderna Inc. (Nasdaq: MRNA)
Product Industry RNA-based therapeutic
Persons Person Bancel, Stéphane (Moderna 2011– CEO before bioMérieux 201010 CEO + Eli Lilly)
  Person 2 Termeer, Henri A. (Genzyme 1985–201106 CEO joined Genzyme 1983)
     
Region Region Cambridge, MA
  Country United States (USA)
  Street 161 First Street
  City 02142 Cambridge, MA
  Tel +1-617-714-6500
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
     
    * Document for �About Section�: 
     
   
Record changed: 2021-04-03

Advertisement

Picture [iito] Made Without Love 650x80px

More documents for Moderna (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px




» top